Reduction in PCSK9 levels induced by anacetrapib: an off-target effect?1

Reduction in PCSK9 levels induced by anacetrapib: an off-target effect?1

Bibliographic Details
Main Authors:	Philip J. Barter, Fatiha Tabet, Kerry-Anne Rye
Format:	Article
Language:	English
Published:	Elsevier 2015-11-01
Series:	Journal of Lipid Research
Online Access:	http://www.sciencedirect.com/science/article/pii/S0022227520354730

Similar Items

Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9[S]
by: Sam J.L. van der Tuin, et al.
Published: (2015-11-01)

Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib[S]
by: Michael Davidson, et al.
Published: (2013-02-01)

Anacetrapib as a potential cardioprotective strategy
by: Di Bartolo BA, et al.
Published: (2017-12-01)

Phage display for targeting PCSK9
by: Nicola Ferri
Published: (2021-03-01)

Anacetrapib: potential for the prevention and treatment of coronary heart disease
by: Steen DL, et al.
Published: (2013-04-01)

PCSK9: A Potential Therapeutic Target for Sepsis
by: Yuan Yuan, et al.
Published: (2020-01-01)

The metabolism and anti-atherogenic properties of HDL
by: Kerry-Anne Rye, et al.
Published: (2009-01-01)

The PCSK9 decade
by: Gilles Lambert, et al.
Published: (2012-12-01)

Dalcetrapib and anacetrapib differently impact HDL structure and function in rabbits and monkeys
by: Mathieu R. Brodeur, et al.
Published: (2017-07-01)

Trafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal Domain.
by: Steve Poirier, et al.
Published: (2016-01-01)

Serum PCSK9 levels, but not PCSK9 polymorphisms, are associated with CAD risk and lipid profiles in southern Chinese Han population
by: Gaojun Cai, et al.
Published: (2018-09-01)

PCSK9: A New Target for Lipid-Lowering Therapy
by: Nutjaree Jeenduang
Published: (2014-04-01)

PCSK9 function and physiology*1
by: Andrew S. Peterson, et al.
Published: (2008-06-01)

Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias?
by: Theodosios D. Filippatos, et al.
Published: (2017-09-01)

The predictive utility of circulating PCSK9 levels on diabetes mellitus
by: Jia Peng, et al.
Published: (2021-02-01)

Plasma levels of PCSK9 and phenotypic variability in familial hypercholesterolemia
by: R. Huijgen, et al.
Published: (2012-05-01)

Reduction of circulating PCSK9 and LDL-C levels by liver-specific knockdown of HNF1α in normolipidemic mice[S]
by: Vikram Ravindra Shende, et al.
Published: (2015-04-01)

Targeting PCSK9: a promising adjuvant strategy in cancer immunotherapy
by: Catarina R. Almeida, et al.
Published: (2021-03-01)

PCSK9: A Key Target for the Treatment of Cardiovascular Disease (CVD)
by: Saeideh Sobati, et al.
Published: (2020-08-01)

Potential of PCSK9 as a new target for the management of LDL cholesterol
by: Mombelli G, et al.
Published: (2015-07-01)

Errata. PCSK9 function and physiology1
by: Andrew S. Peterson, et al.
Published: (2008-07-01)

Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib
by: Ronald M. Krauss, et al.
Published: (2012-03-01)

Naturally Occurring PCSK9 Inhibitors
by: Maria Pia Adorni, et al.
Published: (2020-05-01)

PCSK9 monoclonal antibodies: An overview
by: Rasha Kaddoura, et al.
Published: (2020-01-01)

PCSK9 Antibodies for the Treatment of Hypercholesterolemia
by: Ioanna Gouni-Berthold, et al.
Published: (2014-12-01)

Expression of PCSK9 in Hepatocellular Carcinoma
by: Bhat, Mamatha
Published: (2012)

PCSK9 and cancer: Rethinking the link
by: Khadijeh Mahboobnia, et al.
Published: (2021-08-01)

Pleiotropic Effects of PCSK-9 Inhibitors
by: Marcin Basiak, et al.
Published: (2021-03-01)

Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly
by: Ranheim Trine, et al.
Published: (2007-03-01)

Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts
by: My-Anh Nguyen, et al.
Published: (2014-02-01)

PCSK9 Levels Are Raised in Chronic HCV Patients with Hepatocellular Carcinoma
by: Silvano Fasolato, et al.
Published: (2020-09-01)

Plasma PCSK9 levels are significantly modified by statins and fibrates in humans
by: Mbikay Majambu, et al.
Published: (2008-06-01)

The impact of Niacin on PCSK9 levels in vervet monkeys (Chlorocebus aethiops)
by: Ngqaneka, Thobile
Published: (2021)

The impact of Niacin on PCSK9 levels in vervet monkeys (Chlorocebus aethiops)
by: Ngqaneka, Thobile
Published: (2021)

The impact of Niacin on PCSK9 levels in vervet monkeys (Chlorocebus aethiops)
by: Ngqaneka, Thobile
Published: (2021)

Cardioprotective functions of HDLs1
by: Kerry-Anne Rye, et al.
Published: (2014-02-01)

PCSK9 and its clinical importance with the new therapeutic targets against dyslipidemia
by: Carlos Eduardo dos Santos Ferreira, et al.

Impact of PCSK9 on CTRP9-Induced Metabolic Effects in Adult Rat Cardiomyocytes
by: Susanne Rohrbach, et al.
Published: (2021-02-01)

Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters
by: Jose Castro-Perez, et al.
Published: (2011-11-01)

Inhibition of PCSK9 does not improve lipopolysaccharide-induced mortality in mice
by: Jean-Mathieu Berger, et al.
Published: (2017-08-01)